Results 11 to 20 of about 3,260 (145)
Zanubrutinib-induced liver injury: a case report and literature review [PDF]
BMC Gastroenterology, 2021 Background Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies.
Edmond Atallah +5 more
doaj +2 more sources
eJHaem, 2023 Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 ...
Thi H. O. Nguyen +19 more
doaj +3 more sources
Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report [PDF]
Frontiers in OncologyObjectivesThis case report aims to evaluate the efficacy of zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), in achieving durable disease control for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Zhenhui Lv +4 more
doaj +2 more sources
Blood Advances: Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who harbor del(17p) and/or tumor protein p53 (TP53) mutations represent a high-risk population with a historically poor prognosis.
Constantine S. Tam +20 more
doaj +2 more sources
Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database
BMJ OpenObjective Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor that has been approved for the treatment of several B cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on the
Ping Huang +6 more
doaj +2 more sources
BMC Chemistry, 2023 Background This study establishes a UHPLC‒MS/MS method for the detection of zanubrutinib and explores its interaction with fluconazole and isavuconazole in rats. Methods A protein precipitation method using acetonitrile was used to prepare plasma samples
Peng-fei Tang +6 more
doaj +2 more sources
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
Cells, 2022 Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient’s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and
Javier Muñoz +3 more
doaj +2 more sources
Molecules, 2023 Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun +7 more
doaj +2 more sources
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis from the Randomized Phase III ASPEN Study [PDF]
, 2023 The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN.
Castillo, Jorge J. +33 more
core +5 more sources
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings [PDF]
Frontiers in ImmunologyBackgroundCytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related respiratory failure.
Steven P. Treon +35 more
doaj +2 more sources